Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
Trial Parameters
Brief Summary
To explore the efficacy of Houyanqing Oral Liquid combined with conventional treatment in preventing and treating radiation-induced oral mucositis, so as to improve the quality of life of nasopharyngeal carcinoma patients received radiotherapy.
Eligibility Criteria
Inclusion Criteria: 1. Staged as Stage I-IV according to the 9th edition of the TNM Classification of Malignant Tumors formulated by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC); 2. Age: 18 to 75 years old; 3. Karnofsky Performance Status (KPS) score ≥ 80 before treatment; 4. No oral diseases (such as oral mucositis or salivary gland damage) before radiotherapy; 5. Requiring radical radiotherapy; 6. The patient has signed the informed consent form and is willing and able to comply with the study's follow-up visits, treatment plan, laboratory tests, and other research procedures. Exclusion Criteria: 1. Patients with confirmed tumor recurrence, distant tumor metastasis, or who have received other anti-tumor treatments; 2. Previous history of head and neck radiotherapy; 3. Known allergy to the drugs used in this study (Houyanqing Oral Liquid, any conventional treatment drugs); 4. Local use of Houyanqing Oral Liquid, Recombinant Human